


Cancer Risk Evaluation

Methods and Trends

Edited by Günter Obe, Burkhard Jandrig,
Gary E. Marchant, Holger Schütz,
and Peter M. Wiedemann



 WILEY-
BLACKWELL

Edited by
Günter Obe, Burkhard Jandrig,
Gary E. Marchant, Holger Schütz,
and Peter M. Wiedemann

Cancer Risk Evaluation

Related Titles

Hsu, C.-H., Stedeford, T. (eds.)

Cancer Risk Assessment

Chemical Carcinogenesis, Hazard Evaluation, and Risk Quantification

2010

ISBN: 978-0-470-23822-6

Wiedemann, P. M., Schütz, H. (eds.)

The Role of Evidence in Risk Characterization

Making Sense of Conflicting Data

2008

ISBN: 978-3-527-32048-6

Edited by
Günter Obe, Burkhard Jandrig, Gary E. Marchant,
Holger Schütz, and Peter M. Wiedemann

Cancer Risk Evaluation

Methods and Trends

 **WILEY-BLACKWELL**

The Editors

Prof. Dr. Günter Obe

Ret. from University Duisburg-Essen
Present address:
Gershwinstrasse 33
14513 Teltow
Germany

Dr. Burkhard Jandrig

Max-Delbrück-Center
for Molecular Medicine (MDC)
Robert-Rössle-Str. 10
13125 Berlin
Germany

Prof. Dr. Gary E. Marchant

S. Day O'Connor College of Law
Arizona State University
Tempe, AZ 85287-796
USA

Dipl. Päd. Holger Schütz

Research Center Jülich, Inst.
of Neuroscience and Medicine (INM-8)
52425 Jülich
Germany

Prof. Dr. Peter M. Wiedemann

Karlsruher Institut für Technologie (KIT)
TAB – Büro für Technikfolgen-
Abschätzung beim Deutschen Bundestag
Neue Schönhauser Straße 10
10178 Berlin
Germany

Cover

Microscopic Cancer Cell © PhotoDisc/Getty Images

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty can be created or extended by sales representatives or written sales materials. The Advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2011 Wiley-VCH Verlag & Co. KGaA,
Boschstr. 12, 69469 Weinheim, Germany

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical, and Medical business with Blackwell Publishing.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Cover Design Adam-Design, Weinheim

Typesetting Thomson Digital, Noida, India

Printing and Binding betz-druck GmbH, Darmstadt

Printed in the Federal Republic of Germany

Printed on acid-free paper

ISBN: 978-3-527-32753-9

ePDF ISBN: 978-3-527-63462-0

ePub ISBN: 978-3-527-63463-7

Mobi ISBN: 978-3-527-63464-4

oBook ISBN: 978-3-527-63461-3

Contents

Preface XIII

List of Contributors XV

1 Introduction 1
References 6

Part One Models and Approaches 9

2 Models of Cancer Development: Genetic and Environmental Influences 11
Burkhard Jandrig

2.1 Introduction 11
2.2 Specific Characteristics of Tumors 12
2.3 Tumorigenesis as a Multistep Process 15
2.4 Epigenetic Changes in Cancer Development 16
2.5 miRNAs and Cancer 17
2.6 Cancer Stem Cells 18
2.7 Cancer and the Environment 19
2.8 Systems Analysis of Cancer 20
2.9 Outlook 21
References 22

3 Endogenous DNA Damage and Its Relevance for the Initiation of Carcinogenesis 25
Bernd Epe and Markus Fufser

3.1 Introduction 25
3.2 Types and Generation of Oxidative DNA Modifications 26

3.2.1 Spontaneous Hydrolysis Products in DNA 27
3.2.2 Oxidation Products in DNA 27
3.2.3 Alkylation Products in DNA 28
3.2.4 DNA Modifications Resulting from DNA Replication and Repair 28

3.3	Repair of Endogenous DNA Modifications	29
3.3.1	Basic Mechanisms	29
3.3.2	Analysis of Repair Activities	30
3.4	Basal Steady-State Levels	30
3.5	Contribution of Endogenous DNA Modifications to Cancer Risk	33
	References	35
4	The IARC Monographs Programme: Cancer Hazard Identification as a First Step in Cancer Risk Assessment and Cancer Prevention	41
	<i>Robert A. Baan and Vincent J. Cogliano</i>	
4.1	Introduction	41
4.1.1	The Origin of the IARC Monographs Programme	41
4.1.2	The IARC Monographs Programme: Objective and Scope	42
4.1.3	Selection of Agents for Review	42
4.1.4	The Evaluation Process	42
4.2	Formaldehyde, Nasopharyngeal Cancer, and Leukemia: Evolution in Evaluation	43
4.2.1	Summary of Epidemiological Data Reviewed in Volume 29	45
4.2.2	Summary of Epidemiological Data Reviewed in Supplement 7	46
4.2.3	Summary of Epidemiological Data Reviewed in Volume 62	47
4.2.4	Summary of Epidemiological Data Reviewed in Volume 88	47
4.2.5	Summary of Epidemiological Data Reviewed in Volume 100-F	48
4.3	Herbal Medicines, <i>Aristolochia</i> Plant Species, and Aristolochic Acid Nephropathy	50
4.3.1	Summary of Epidemiological Data in Volume 82	51
4.3.2	Summary of Mechanistic Data on <i>Aristolochia</i> -Induced Urothelial Cancer (Volume 100-A; Ref. [52]): Identification of Aristolochic Acid as the Key Carcinogen	52
4.4	Concluding Remarks	54
4.4.1	Formaldehyde	54
4.4.2	<i>Aristolochia</i> spp and Aristolochic Acid	55
	References	56
Part Two	Epidemiological Research	61
5	The Role of Epidemiology in Cancer Risk Assessment of Nonionizing Radiation	63
	<i>Joachim Schüz, Gabriele Berg-Beckhoff, Brigitte Schlehofer, and Maria Blettner</i>	
5.1	Introduction	63

- 5.2 Brief Outline of Common Epidemiological Study Designs 64
- 5.3 Criteria for Evaluating the Plausibility of Epidemiological Findings 66
- 5.4 Bias and Errors in Epidemiological Studies 71
- 5.5 Compatibility between Study Findings and Time Trends in the Occurrence of Disease 74
- 5.6 Discussion 74
References 78

6 The Role of Epidemiology in Cancer Risk Assessment of Ionizing Radiation 83

Richard Wakeford

- 6.1 Introduction 83
- 6.2 Japanese Atomic Bomb Survivors 84
- 6.3 Medical Exposures 88
- 6.4 Occupational Exposures 89
- 6.5 Environmental Exposures 93
- 6.6 Conclusions 97
References 97

Part Three Animal Studies 103

7 Animal Studies on RF EMF Cancer Effects 105

Clemens Dasenbrock and Jochen Buschmann

- 7.1 Introduction 105
 - 7.1.1 Carcinogenesis 105
 - 7.1.2 Principles of Carcinogenicity/Toxicity Testing 106
- 7.2 Exemplary Carcinogenicity Studies Testing the Possible Health Effects Related to Mobile Telephones and Base Stations (PERFORM-A) 107
 - 7.2.1 Material and Methods 109
 - 7.2.2 Results 112
 - 7.2.3 Discussion 115
 - 7.2.4 Conclusions 117
- 7.3 Research Gaps 117
 - 7.3.1 Exposure Assessment 118
 - 7.3.2 Mode of Action 119
 - 7.3.3 Susceptibility 119
 - 7.3.4 Extrapolation 119
- 7.4 Proposed Research Strategy 120
 - 7.4.1 Interaction between Hypothesis-Driven Studies and “Apical” Tests 120
 - 7.4.2 Thermal versus Nonthermal Effects 121
 - 7.4.3 Role of “Omics” Studies 122

7.5	Summary	122
	References	123
8	Animal Studies in Carcinogen Identification: The Example of Power Frequency (50/60 Hz) Magnetic Fields	125
	<i>David L. McCormick</i>	
8.1	Introduction	125
8.2	Strengths and Limitations of Epidemiology Studies of EMF as a Cancer Hazard	126
8.3	Strengths and Limitations of Experimental Studies of EMF as a Cancer Hazard	128
8.4	Role of Mechanistic Studies in EMF Hazard Assessment	129
8.5	Oncogenicity Studies of EMF	129
8.5.1	EMF as a Possible Risk Factor for Cancer: Epidemiology Studies	129
8.5.2	EMF as a Possible Risk Factor for Cancer: Experimental Studies	130
8.6	Conclusions	133
	References	134
Part Four	Genotoxicity Studies	137
9	Chromosomal Aberrations in Human Populations and Cancer	139
	<i>Günter Obe, David C. Lloyd, and Marco Durante</i>	
9.1	Introduction	139
9.2	Chromosomal Aberrations and Their Spontaneous Frequencies in Human Peripheral Lymphocytes	139
9.3	Micronuclei	143
9.4	Sister Chromatid Exchanges	144
9.5	Age Dependency of CA, MN, and SCE	144
9.6	Origin of CA in HPL	146
9.7	Ionizing Radiation and Chromosomal Aberrations	146
9.8	CA and Cancer in Human Populations	151
	References	155
10	Cytogenetic Studies in Mammalian Somatic Cells Exposed to Radio Frequency Radiation: A Meta-Analysis	163
	<i>Vijayalaxmi and Thomas J. Prihoda</i>	
10.1	Introduction	163
10.2	Materials and Methods	163
10.2.1	Meta-Analysis	164

10.2.2	Magnitude of Difference between RFR-Exposed and Controls ($E-C$)	164
10.2.3	Effect Size or Standardized Mean Difference	164
10.2.4	Multiple Regression Analysis	165
10.2.5	Heterogeneity	165
10.2.6	Historical Database	165
10.3	Results	166
10.3.1	Multiple Regression Analysis and Heterogeneity	169
10.3.2	Comparison of Meta-Analysis Data with Those in Historical Database for CA, MN, and SCE	171
10.4	Cytogenetic Endpoints as Biomarkers for Cancer Risk	171
10.5	Perspective from Meta-Analysis and Conclusions	171
	References	172

Part Five Omics: A New Tool for Cancer Risk Assessment? 175

11 Genomics and Cancer Risk Assessment 177

Michal R. Schweiger and Bernd Timmermann

11.1	Introduction	177
11.2	Tissue Material	178
11.3	Analysis Technologies	179
11.3.1	DNA Microarrays	179
11.3.2	DNA Sequencing	180
11.3.3	Next-Generation Sequencing	181
11.3.4	Current Technologies	181
11.3.5	Targeted DNA Sequencing	185
11.3.6	Copy Number Variations	185
11.3.7	DNA Methylation	186
11.3.8	Transcriptome Analyses	187
11.4	Outlook for Individualized Cancer Treatment	188
	References	189

12 Transcriptomics and Cancer Risk Assessment 195

Wolfgang Kemmner

12.1	Introduction	195
12.2	Sample Preparation, Technical Issues, and Data Analysis	196
12.2.1	How to Use Your Gene Signatures to Carry Out Cancer Risk Assessment	198
12.2.2	You Need a Hypothesis!	200
12.2.3	Microarray Applications in Cancer Research	201
12.2.4	What Are the Questions of Concern for the Clinical Management of Cancer?	201
12.3	Conclusions	203
	References	204

13	Proteomics and Cancer Risk Assessment	207
	<i>Alexander Schramm</i>	
13.1	Introduction	207
13.2	Sample Preparation and Storage: A Challenge in Clinical Settings	208
13.3	Caveats and Hurdles in Protein Analysis Using Cancer Specimen and Clinical Samples	208
13.4	Separation and Fractionation of Protein Mixtures as a Prerequisite to Proteomic Analyses and Protein Quantification	209
13.5	Identification of Proteins by Mass Spectrometry	210
13.6	Array-Based Proteome Technology in Cancer Research	211
13.7	The Present and the Future: Proteomics for Individualized Cancer Therapy	212
	References	214
Part Six	Current Use of Omics Studies for Cancer Risk Assessment	219
14	Omics in Cancer Risk Assessment: Pathways to Disease	221
	<i>Christopher J. Portier and Reuben Thomas</i>	
14.1	Introduction	221
14.2	“Omics” Data in Cancer Risk Assessment	223
14.3	High-Throughput Screening	226
14.4	Discussion	228
	References	230
15	What Have “Omics” Taught Us about the Health Risks Associated with Exposure to Low Doses of Ionizing Radiation	233
	<i>William F. Morgan and Marianne B. Sowa</i>	
15.1	Introduction	233
15.2	Pre-“Omics”	234
15.3	Functional Genomics	234
15.4	Gene Expression Profiling for Nontargeted Effects Induced by Exposure to Ionizing Radiation	235
15.5	Gene Expression Profiling for Adaptive Responses Induced by Exposure to Ionizing Radiation	236
15.6	<i>In Vivo</i> Gene Profiling after Irradiation	237
15.7	Radiation-Induced Oscillatory Signaling	238
15.8	Proteomic Profiling after Exposure to Ionizing Radiation	239
15.9	Metabolomic Profiling after Exposure to Ionizing Radiation	240
15.10	Conclusions	241
	References	241
16	Transcriptomics Approach in RF EMF Research	245
	<i>Meike Mevissen</i>	
16.1	Introduction	245

16.2	Transcriptomics in RF EMF Research	246
16.3	Discussion	255
	References	259
17	Proteomics Approach in Mobile Phone Radiation Research	265
	<i>Dariusz Leszczynski</i>	
	References	272
Part Seven Challenges for Risk Management 275		
18	Evaluating the Reliability of Controversial Scientific Results	277
	<i>Alexander Lerchl</i>	
18.1	Introduction	277
18.2	Detection of Scientific Misconduct	278
18.2.1	Before Publication	278
18.2.2	After Publication	281
18.3	Committee on Publication Ethics	285
18.4	Conclusions	286
	References	287
19	Comparative Risk Assessment with Ionizing and Nonionizing Radiations	289
	<i>Jürgen Kiefer</i>	
19.1	Introduction	289
19.2	Review of Different Radiation Types	291
19.2.1	Ionizing Radiation	291
19.2.2	Ultraviolet Radiation	294
19.2.3	Visible Light	296
19.2.4	Infrared	297
19.2.5	Terahertz Radiation	297
19.2.6	Mobile Communication	298
19.2.7	Radio Frequency	300
19.2.8	Extremely Low Frequencies	301
19.3	Discussion	302
	References	303
20	Communicating about Uncertainties in Cancer Risk Assessment	311
	<i>Peter Wiedemann and Holger Schütz</i>	
20.1	Introduction	311
20.2	The Concept of Uncertainty	312
20.3	Reasons for Communicating Uncertainties	313
20.4	Findings on Communicating Uncertainties	315
20.4.1	Preferences with Respect to Being Informed about Uncertainty	315

20.4.2	Interpretation of Uncertainties in Risk Assessment	316
20.4.3	Effects of Reporting Uncertainty of Risk Estimates on Risk Perception and Credibility	319
20.5	Explaining Inconclusive Evidence	321
20.6	Conclusions	322
20.6.1	Should Uncertainties in Cancer Risk Assessments Be Disclosed?	322
20.6.2	What Types of Uncertainty Should Be Addressed?	323
20.6.3	In Which Format Should Uncertainties Be Described?	323
20.6.4	In What Detail Should Uncertainty Be Revealed?	324
	References	325

21 The Precautionary Principle and Radio Frequency Exposure from Mobile Phones 329

Gary E. Marchant

21.1	Introduction	329
21.2	Background on the Precautionary Principle	329
21.3	Pros and Cons of the Precautionary Principle	330
21.4	Applying the Precautionary Principle to Radio Frequency Electromagnetic Fields	333
21.4.1	Should the Precautionary Principle Apply to Radio Frequency Electromagnetic Fields?	333
21.4.2	What Action Does the Precautionary Principle Recommend for Radio Frequency?	335
21.5	Conclusions	338
	References	338

Index 341

Preface

Both the modern biomedical research such as genomics and proteomics and the rapid advances in high-throughput screening molecular technologies have revolutionized the knowledge about functional and regulatory genomics, which is beginning to make an immense impact on our understanding of human health and disease. These developments have also brought great hope to improve cancer risk assessment, even to solve scientific controversies about cancer risk claims, such as the debate whether electromagnetic fields from mobile telephony cause cancer in humans.

During the past few years, we were able to focus on this question in an integrated multidisciplinary research project on the implications of modern biomedicine on risk assessment (IMBA), sponsored by the Helmholtz Association of German Research Centres. As a health technology assessment project, IMBA analyzed how new developments in biomedicine, which are often summarized under the term “toxicogenomics,” will transform the present risk management framework. IMBA looked into a wide range of scientific and social challenges that deserve careful attention, particularly on issues related to risk assessment, risk perception, and risk communication.

In 2008, we organized an international workshop in Berlin as part of the IMBA project. The aim of the workshop was to compare the potential of genomics and traditional approaches used in cancer risk assessment, particularly genotoxicity studies, with regard to their potential to inform assessment of unclear risks, that is, risks where evidence is insufficient for a conclusive risk assessment. The unclear risks chosen for discussion were radio frequency electromagnetic fields. Topics such as the validity and reliability of genotoxic research for cancer risk assessment, the prospects of toxicity testing and risk assessment, and the implications for policy making were critically reviewed and evaluated by experts in the fields of ionizing and nonionizing radiation, genotoxicity, molecular medicine, and epidemiology.

The discussions during the workshop motivated us to plan a publication on these topics. Further impetus came from the ongoing societal debate on the health implications of electromagnetic fields, which seems not to be solved but stimulated by new molecular biomarker studies and high-throughput technologies in this field. We think that in a climate of excitement about the promises of molecular medicine, it is crucial to explore the validity of molecular biomarkers and evaluate their added

value for risk assessment. We hope that this book will contribute to effective interdisciplinary communication and collaboration in the fields of molecular biology, cancer research, risk assessment, and public health policy.

We are grateful to all authors of the book for investing their valuable time in writing their contributions and participating in the review process in order to make the book valuable for all readers. Last but not least, we appreciate the support of the Helmholtz Association of German Research Centres.

Berlin, December 2010

*Günter Obe, Burkhard Jandrig,
Gary E. Marchant, Holger Schütz,
Peter M. Wiedemann*

List of Contributors

Robert A. Baan

WHO–International Agency for
Research on Cancer
The IARC Monographs Programme
150, cours Albert Thomas
69372 Lyon Cedex 08
France

Gabriele Berg-Beckhoff

Unit for Health Promotion Research
Institut of Public Health
University of Southern Denmark
Niels Bohrs Vej 9
6700 Esbjerg
Denmark

Maria Blettner

Johannes Gutenberg-University of
Mainz
Institute of Medical Biostatistics,
Epidemiology, and Informatics
Obere Zahlbacher Straße 69
55101 Mainz
Germany

Jochen Buschmann

Fraunhofer Institute for Toxicology and
Experimental Medicine
Department of Toxicology &
Environmental Hygiene
Nikolai-Fuchs-Strasse 1
30625 Hannover
Germany

Vincent J. Cogliano

Acting Director, Integrated Risk
Information System (IRIS)
National Center for Environmental
Assessment
U.S. Environmental Protection Agency
1200 Pennsylvania Ave NW (8601P)
Washington DC 20460
USA

Clemens Dasenbrock

Fraunhofer Institute for Toxicology and
Experimental Medicine
Department of Toxicology &
Environmental Hygiene
Nikolai-Fuchs-Strasse 1
30625 Hannover
Germany

Marco Durante

GSI Helmholtzzentrum für
Schwerionenforschung
Biophysics Department
Planckstrasse 1
64291 Darmstadt
Germany

and

Technical University of Darmstadt
Department of Condensed Matter
Physics
Hochschulstraße 3
46289 Darmstadt
Germany

Bernd Epe

University of Mainz
Institute of Pharmacy and Biochemistry
Staudingerweg 5
55128 Mainz
Germany

Markus Fußer

University of Mainz
Institute of Pharmacy and Biochemistry
Staudingerweg 5
55128 Mainz
Germany

Burkhard Jandrig

Max Delbrück Center for Molecular
Medicine
Robert-Rössle-Str. 10
13125 Berlin
Germany

Wolfgang Kemmner

Max Delbrück Center for Molecular
Medicine
Experimental and Clinical Research
Center (ECRC)
Research Group Surgical Oncology
Robert-Rössle-Str. 10
13125 Berlin
Germany

Jürgen Kiefer

Universität Giessen
Am Dornacker 4
35435 Wettenberg
Germany

Alexander Lerchl

Jacobs University Bremen
School of Engineering and Science,
Research II
Campus Ring 6
28759 Bremen
Germany

Dariusz Leszczyński

STUK – Radiation and Nuclear Safety
Authority
Laippatie 4
00881 Helsinki
Finland

David C. Lloyd

Health Protection Agency
Chilton
Didcot OX11 0RQ
UK

Gary E. Marchant

Arizona State University Sandra
Day O'Connor College of Law
P.O. Box 877906
Tempe, AZ 85287-796
USA

David L. McCormick

IIT Research Institute
10 West 35th Street
Chicago, IL 60616
USA

Meike Mevissen

University of Bern
Vetsuisse Faculty
Department of Clinical Research and
Veterinary Public Health
Division Veterinary Pharmacology and
Toxicology
Länggassstrasse 124
3012 Bern
Switzerland

William F. Morgan

Pacific Northwest National Laboratory
Cell Biology and Biochemistry
P.O. Box 999, MSIN P7-56
Richland, WA 99354
USA

Günter Obe

Ret. from University Duisburg-Essen
Present address:
Gershwinstrasse 33
14513 Teltow
Germany

Christopher J. Portier

National Center for Environmental
Health/Agency for Toxic Substances
and Disease Registry
Centers for Disease Control
and Prevention
1600 Clifton Road
Atlanta, GA 30333

Thomas J. Prihoda

University of Texas Health Science
Center
Department of Pathology
San Antonio, TX 78229
USA

Brigitte Schlehofer

German Cancer Research Centre
Unit of Environmental Epidemiology
Im Neuenheimer Feld 280
69120 Heidelberg
Germany

Alexander Schramm

Universitätsklinikum Essen,
Pädiatrie III
Onkologisches Labor
Hufelandstr. 55
45122 Essen
Germany

Holger Schütz

Research Center Jülich
Institute of Neuroscience and Medicine
(INM-8)
52425 Jülich
Germany

Joachim Schüz

International Agency for Research on
Cancer (IARC)
Section of Environment and Radiation
150, cours Albert Thomas
69372 Lyon Cedex 08
France

Michal R. Schweiger

Max-Planck Institute for Molecular
Genetics
Department of Vertebrate Genomics
Ihnestrasse 63-73
14195 Berlin
Germany

Marianne B. Sowa

Pacific Northwest National Laboratory
Cell Biology and Biochemistry
P.O. Box 999, MSIN P7-56
Richland, WA 99354
USA

Reuben Thomas

National Institute of Environmental
Health Sciences
Laboratory of Toxicology and
Pharmacology
Environmental Systems Biology
P.O. Box 12233, MD B2-08
Research Triangle Park, NC 27709
USA

Bernd Timmermann

Max-Planck Institute for Molecular
Genetics
Innestrasse 63–73
14195 Berlin
Germany

Vijayalaxmi

University of Texas Health Science
Center
Department of Radiology
San Antonio, TX 78229
USA

Richard Wakeford

The University of Manchester
Dalton Nuclear Institute
Pariser Building – G Floor
P.O. Box 88, Sackville Street
Manchester M60 1QD
UK

Peter M. Wiedemann

Karlsruher Institut für Technologie
(KIT)
TAB – Büro für Technikfolgen-
Abschätzung beim Deutschen
Bundestag
Neue Schönhauser Straße 10
10178 Berlin
Germany

1

Introduction

Cancer is one of the leading causes of human mortality. Over the past 30 years, the global burden of cancer has more than doubled. According to the recent World Cancer Report, published by the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), in 2008 there were 7 million deaths from cancer. Affected by the still growing and aging world population, this figure is expected to increase to 17 million annually by 2030 [1]. While many environmental cancer risk factors, such as exposures to ionizing radiation or tobacco smoke, alcohol consumption, or excessive sun exposure, have been established [2], assessments of cancer hazards and risks are difficult and often highly uncertain. Of the more than 900 agents that have been evaluated by IARC, only 12% have been classified as being clearly carcinogenic to humans [3]. And even if an agent has been identified as a carcinogen, the risk it poses to a given population is often hard to estimate. The reasons for these difficulties are manifold. First of all, there are different types of cancer that differ in their etiology. Another reason – and that is the focus of this book – is that cancer causation is hard to investigate. Experimental studies in humans are for obvious ethical reasons not possible, thus cancer risk assessment has to rely on indirect evidence.

At present, assessments of carcinogenicity are based on three pillars: epidemiological studies in humans, studies in experimental animals, and genotoxicity studies. Epidemiological studies aim at identifying the causes of cancer by studying the covariation between exposure to an agent and cancer incidence. Although there is a long debate on if and when epidemiology actually can provide causal evidence [4], there is little disagreement that epidemiological studies are the most important source of knowledge for cancer risk assessment [2, 5]. In studying the carcinogenicity of agents, epidemiological studies have to rely on given exposures to the respective agents, for instance, radon emanating from the soil or electromagnetic fields emitted from mobile communication devices. These conditions are usually not under control of the investigators, and although epidemiologists have developed an elaborate methodology to match specific study demands [6], problems such as bias and confounding frequently limit the conclusiveness of their results.

Compared to epidemiology, animal studies have the advantage of permitting experimental designs, where (at least in principle) everything can be controlled. This allows the most stringent test of a causal relationship between the exposure to an agent and an adverse effect. At least for chemical agents, there is a kind of “gold standard” that is used for carcinogenicity testing, which includes 2-year studies with rodents [7]. However, these studies are time consuming and expensive, limiting the number of agents that are tested [2]. Beside ethical considerations regarding the use of animals in research, the appropriateness of animal models for investigating and predicting human diseases has been disputed [8]. It should also be noted that this gold standard is not so well established for some physical agents. For example, many animal studies investigating the potential carcinogenicity of radio frequency electromagnetic fields (RF EMF) use only one type of animals and often for a short period [9]. An important limitation of using animal studies for carcinogenicity testing is that the experimental results always have to be extrapolated to humans, which is of course acknowledged in evaluations of evidence for cancer risk assessment [2, 5].

Basically, the same holds for genotoxicity studies, where experimental findings also have to be evaluated with regard to their implications for humans. Their value lies in the fact that cancer results primarily from genetic changes in single cells. Therefore, agents that are able to damage cellular DNA lead to mutations and then possibly to cancer. For instance, people exposed to ionizing radiation have both an elevated cancer risk and elevated frequencies of chromosomal aberrations in their peripheral lymphocytes, showing the mutagenic activity of ionizing radiation. Mutations are initiating events for the development of cancer and therefore testing of various agents for their possible mutagenicity is an important part of cancer risk assessment [10].

Over the past years, new technologies have been developed that promise new insight into cancer risk assessment by focusing on the role of the genome for understanding cancer initiation and development [11, 12]. These so-called omics technologies include genomics for DNA variations, transcriptomics for messenger RNA, proteomics for peptides and proteins, and metabolomics for intermediate products of metabolism. Technological breakthroughs allow simultaneous examination of thousands of genes, transcripts, proteins, and metabolites with high-throughput techniques and analytical tools to extract information. These new technologies are expected to provide a highly sensitive detection of low-dose effects, more reliable extrapolation of risk estimates across doses, routes, and species, and valuable insight into the mechanism of action of toxicants. Overall, the ability to classify chemicals and other stressors based on their effects at omics level would permit the development of new testing strategies in cancer risk assessment. At present, genomics- and transcriptomics-based approaches are most promising, while metabolomics, though in principle quite potent, is quite nascent in its development, as present techniques and the methodology are far away from inspecting the whole metabolome. High-throughput screening technologies have their own technical limitations and uncertainties. The transcriptome and proteome are highly dynamic and change rapidly and dramatically in response to perturbations or even during normal cellular events. The modern screening technologies still have

the problem of reproducibility and variability between studies and are prone to produce false positive results [13, 14].

An important aspect here is quality control of scientific investigations. Although in general not limited to the omics field, the huge amount of data produced with microarray experiments and the extensive data processing required for analysis make open data accessibility to allow independent reevaluation of findings an important claim, which is increasingly acknowledged in the scientific community [15, 16]. Another aspect of quality control is how to evaluate the reliability of controversial scientific results. As said before, it is difficult to rule out errors in high-throughput screening research. Even more complicated is the proper dealing with fraud suspicions. Although fraud in science is by no means a new phenomenon, recent scandals in highly prestigious scientific journals have also called the public's attention to this issue [17]. Thus, the highly welcome new approaches to cancer risk assessment also call for the establishment of rules that allow a careful evaluation of study results. Furthermore, better risk communication is required for informing health professionals, the media, and the general public about the meaning of omics findings for risk assessment [18]. A particular problem here is if and when uncertainties in risk assessment should be communicated to a nonexpert audience. On a more general level, the question arises how these uncertainties should be addressed in risk management. This is likely to intensify the current debate about the application of the precautionary principle. Of course, these problems are not specific to omics; however, apart from providing new knowledge for risk assessment, omics is also likely to introduce new uncertainties [19–21].

The following chapters of this book provide insight into new developments of cancer risk assessment and their accompanying scientific discussions. While the focus is on cancer and radiation, especially nonionizing radiation, the various chapters provide the reader with a comprehensive view on cancer biology, cancer assessment methods including epidemiology, animal research, and genotoxicity studies as well as omics approaches and applications. Furthermore, it covers the comparative assessment of radiation risks and addresses policy considerations such as risk communication and application of the precautionary principle.

The book is organized in seven parts. Part One gives an overview of the current understanding of cancer development and approaches to cancer risk assessment. Jandrig (Chapter 2) shows that, apart from mutations, other cellular changes have to be taken into account to understand the complex biology of cancer. Epe and Fußer (Chapter 3) describe the various determinants of generation, repair, and steady-state levels of endogenous DNA modifications. Baan and Cogliano (Chapter 4) provide insight into cancer hazard identification as the first step in cancer risk assessment and cancer prevention, as outlined in the IARC Monographs Programme.

The role of epidemiology in cancer risk assessment is addressed in Part Two. Schüz, Berg-Beckhoff, Schlehofer, and Blettner (Chapter 5) consider the particularly challenging possible adverse health effects of exposure to electromagnetic fields (EMF) that have remained a scientific and political controversy until today. Their first example is the relationship between extremely low-frequency (ELF) fields from power lines and the risk of childhood leukemia. Their second example is the relationship

between RF EMF, specifically those emitted from mobile phones, and the risk of brain tumors. Wakeford (Chapter 6) presents data for cancer risk assessment of ionizing radiation. Among others, he provides cancer risk figures based on epidemiology from Hiroshima survivors and children exposed during and after the Chernobyl accident.

Animal studies are indispensable for cancer hazard identification and results of this type of research are presented in Part Three. Buschmann and Dasenbrock (Chapter 7) refer to recent advances in animal studies on RF EMF testing the possible carcinogenic effects related to cell phones and base stations. On the basis of a comprehensive discussion of the PERFORM-A project, they demonstrate how existing data gaps relevant for risk assessment can be closed. Pointing to the strengths and limitations of epidemiological cancer studies of ELF fields, McCormick (Chapter 8) shows how laboratory animal research can fill gaps in EMF cancer risk assessment. The author discusses the findings of various types of experimental animal studies and comes to the conclusion that available animal data do not support an elevated cancer risk.

Part Four highlights the importance of studying chromosomal damage, which is a highly reliable endpoint for cancer hazard and risk assessment. Obe, Lloyd, and Durante (Chapter 9) outline current approaches to investigating chromosomal aberrations. They argue that elevated frequencies of chromosomal aberrations in peripheral lymphocytes of human populations are associated with elevated cancer frequencies and allow calculation of cancer risks in persons exposed to ionizing radiation, such as astronauts. Vijayalaxmi and Prihoda (Chapter 10) show how meta-analysis as a tool for statistical data synthesis can be used to systematically summarize evidence from cytogenetic studies in mammalian somatic cells that have been exposed to radio frequency radiation. They conclude that exposure to radio frequency radiation does not increase frequencies of chromosomal aberrations and micronuclei, which are two endpoints for chromosomal damage.

The potential of omics technologies as new tools for cancer risk assessment are discussed in Part Five. Technological breakthroughs allow simultaneous examination of thousands of genes, transcripts, proteins, and metabolites with high-throughput techniques and analytical tools to extract information. Modern screening technologies speed up the discovery process and give a broader insight into biochemical events that follow the exposure to potentially harmful agents, such as chemical substances, ionizing radiation, or electromagnetic fields. The different methodologies and techniques are discussed in this part with respect to actual applications and future developments. Schweiger and Timmermann (Chapter 11) explain the huge potential that whole genome approaches afford for understanding complex genetic diseases such as cancer. They provide an overview of the advancement of genome analysis technologies and illustrate how these are used for investigating the mechanisms underlying cancer development. The authors close with an outlook on how the genomics approach might ultimately lead to an individualized cancer treatment. Kemmner (Chapter 12) outlines the use of transcriptomics, or gene expression profiling, in cancer risk assessment, for instance, with regard to classification of human cancers and prediction of cancer recurrence

and metastasis. The author discusses technical challenges of gene expression profiling, such as sample preparation and data analysis, and gives examples of microarray applications in cancer research. Proteomics, the analysis of proteins, and its relevance to cancer risk assessment, is discussed by Schramm (Chapter 13). While proteomics comprises a variety of technical disciplines, its application to cancer risk assessment can be described as a multistep process including sample preparation, separation, quantitation, and protein identification. The author discusses particular challenges of these steps and concludes with an outlook on future developments of proteomics for individualized cancer therapy.

Examples of using omics technologies for risk assessment are described in Part Six. Portier and Thomas (Chapter 14) provide a critical discussion of omics and high-throughput screening strategies concerning cancer risk assessment. First, they discuss the difficulties of traditional cancer risk assessment, in particular with animal studies, and then describe how omics might be used to overcome these problems. They conclude that while there is little doubt that omics will be of major importance for future risk assessment, there is still much research needed, before it finds regulatory approval in risk assessment. Morgan and Sowa (Chapter 15) show how omics might be used for risk assessment of exposure to low-level ionizing radiation. So far, risk assessment had to rely mainly on epidemiological data, for instance, from Japanese A-bomb survivors, but here epidemiology clearly reaches its limits. The authors discuss studies that used gene expression profiling, proteomic profiling, and metabolomic profiling to investigate the effects of low-level ionizing radiation. Their conclusion is that while significant progress has been made in using omics for cancer risk assessment, the future challenge is to integrate the various omics technologies to allow a “systems level” approach. The next two chapters then address how transcriptomics and proteomics can be used for cancer risk assessment of RF EMF. Mevissen (Chapter 16) provides an overview of studies investigating the effects of RF EMF exposure on gene expression. She makes it clear that these studies differ strongly in scientific quality and focus, and are insufficient for drawing conclusions regarding effects the RF EMF exposure has on organisms. A similar picture emerges from the review of proteomics studies that is given by Leszczynski (Chapter 17). So far, only few studies have investigated the effects of RF EMF exposure on the proteome, and many of them have methodological shortcomings.

The last part of the book addresses challenges for risk management. Lerchl (Chapter 18) reports recent examples of apparent scientific misconduct and discusses heuristics that can help detect data fabrication. He also offers some advice how to handle such misconduct appropriately. Kiefer (Chapter 19) offers a comparative risk assessment across the electromagnetic spectrum based on the Bradford Hill criteria. He argues that at present only ionizing radiation fulfils all requirements for cancer hazard identification. Wiedemann and Schütz (Chapter 20) discuss the challenges of communicating about uncertainty in cancer risk assessments to nonexperts. They offer ample evidence that, in contrast to common beliefs, informing about uncertainties might create misperceptions and misunderstandings of risk. Furthermore, they discuss how to explain inconclusive scientific evidence, a task particularly important for hazard assessment. Finally, Marchant (Chapter 21) considers the role

of the precautionary principle in risk management. Weighing the pros and cons, he concludes that despite its rhetorical appeal, the precautionary principle remains problematic in its practical application, which in large part is due to the ambiguity and arbitrariness of the principle.

References

- 1 Boyle, P. and Levin, B. (eds) (2008) *World Cancer Report 2008*, International Agency for Research on Cancer, Lyon.
- 2 Fontham, E.T.H., Thun, M.J., Ward, E., Balch, A.J., Delancey, J.O.L., and Samet, J.M., on behalf of ACS Cancer and the Environment Subcommittee (2009) American Cancer Society perspectives on environmental factors and cancer. *CA Cancer J. Clin.*, **59**, 343–351.
- 3 IARC (2010) *Agents Classified by the IARC Monographs*, vols. 1–100, International Agency for Research on Cancer, Lyon. Available at <http://monographs.iarc.fr/ENG/Classification/index.php> (Accessed July 19, 2010).
- 4 Rothman, K.J. and Greenland, S. (2005) Causation and causal inference in epidemiology. *Am. J. Public Health*, **95**, S144–S150.
- 5 International Agency for Research on Cancer (2006) *Preamble to the IARC Monographs. IARC Monographs Programme on the Evaluation of Carcinogenic Risks to Humans*, International Agency for Research on Cancer. Available at <http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf> (Accessed July 26, 2010).
- 6 Rothman, K.J., Greenland, S., and Lash, T.L. (eds) (2008) *Modern Epidemiology*, 3rd edn, Lippincott Wilkins & Wilkins, Philadelphia, PA.
- 7 Fung, V.A., Barrett, J.C., and Huff, J. (1995) The carcinogenesis bioassay in perspective: application in identifying human cancer hazards. *Environ. Health Perspect.*, **103**, 680–683.
- 8 Hackam, D.G. and Redelmeier, D.A. (2006) Translation of research evidence from animals to humans. *JAMA*, **296**, 1731–1732.
- 9 Dasenbrock, C. (2005) Animal carcinogenicity studies on radiofrequency fields related to mobile phones and base stations. *Toxicol. Appl. Pharmacol.*, **207**, 342–346.
- 10 Parsons, B.L., Myers, M.B., Meng, F., Wang, Y., and McKinzie, P.B. (2010) Oncomutations as biomarkers of cancer risk. *Environ. Mol. Mutagen.* doi: 10.1002/em.20600.
- 11 Bishop, W.E., Clarke, D.P., and Travis, C.C. (2001) The genomic revolution: what does it mean for risk assessment? *Risk Anal.*, **21**, 983–987.
- 12 Simmons, P.T. and Portier, C.J. (2002) Toxicogenomics: the new frontier in risk analysis. *Carcinogenesis*, **23**, 903–905.
- 13 Troester, M.A., Millikan, R.C., and Perou, C.M. (2009) Microarrays and epidemiology: ensuring the impact and accessibility of research findings. *Cancer Epidemiol. Biomarkers Prev.*, **18**, 1–4.
- 14 Vlaanderen, J., Moore, L.E., Smith, M.T., Lan, Q., Zhang, L., Skibola, C.F., Rothman, N., and Vermeulen, R. (2010) Application of omics technologies in occupational and environmental health research: current status and projections. *Occup. Environ. Med.*, **67**, 136–143.
- 15 Kaye, J., Heeney, C., Hawkins, N., de Vries, J., and Boddington, P. (2009) Data sharing in genomics: re-shaping scientific practice. *Nat. Rev. Genet.*, **10**, 331–335.
- 16 Field, D., Sansone, S.-A., Collis, A., Booth, T., Dukes, P., Gregurick, S.K., Kennedy, K., Kolar, P., Kolker, E., Maxon, M., Millard, S., Mugabushaka, A.-M., Perrin, N., Remacle, J.E., Remington, K., Rocca-Serra, P., Taylor, C.F., Thorley, M., Tiwari, B., and Wilbanks, J. (2009) 'Omics data sharing. *Science*, **326**, 234–236.

- 17 Science (2006) Special Online Collection: Hwang et al. Controversy. Available at <http://www.sciencemag.org/sciext/hwang2005/> (Accessed September 10, 2010).
- 18 McBride, C.M., Bowen, D., Brody, L.C., Condit, C.M., Croyle, R.T., Gwinn, M., Khoury, M.J., Koehly, L.M., Korf, B.R., Marteau, T.M., McLeroy, K., Patrick, K., and Valente, T.W. (2010) Future health applications of genomics: priorities for communication, behavioral, and social sciences research. *Am. J. Prev. Med.*, **38**, 556–565.
- 19 Adelman, D.E. (2005) The false promise of the genomics revolution for environmental law. *Harv. Environ. Law Rev.*, **29**, 117–177.
- 20 Battershill, J.M. (2005) Toxicogenomics: regulatory perspective on current position. *Hum. Exp. Toxicol.*, **24**, 35–40.
- 21 Boverhof, D.R. and Zacharewski, T.R. (2006) Toxicogenomics in risk assessment: applications and needs. *Toxicol. Sci.*, **89**, 352–360.

Part One
Models and Approaches

